Adia Nutrition Officially Enters $15.1 Billion Global Stem Cell Market with Domestic Treatments by Successful Opening of First Florida Location
Adia Nutrition (OTC Pink: ADIA) has entered the $15.1 billion global stem cell market through its medical division, Adia Med, with the opening of its first clinic in Winter Park, Florida. The facility offers stem cell treatments using FDA-compliant 361 human cell, tissue, and cellular and tissue-based products (HCT/Ps).
The company aims to provide treatments comparable to international locations like Panama, Mexico, Brazil, and Switzerland, but with the advantage of U.S.-based care. The clinic utilizes umbilical cord stem cells and focuses on treating conditions including inflammation, autoimmune conditions, and orthopedic issues.
Key advantages include quality stem cells from ethical sources, domestic convenience eliminating international travel, and operations under U.S. FDA health regulations emphasizing safety and transparency.
Adia Nutrition (OTC Pink: ADIA) ha fatto il suo ingresso nel mercato globale delle cellule staminali da 15,1 miliardi di dollari attraverso la sua divisione medica, Adia Med, inaugurando la sua prima clinica a Winter Park, Florida. La struttura offre trattamenti con cellule staminali utilizzando prodotti cellulari e tissutali umani (HCT/P) conformi alle normative FDA 361.
L'azienda mira a fornire trattamenti paragonabili a quelli disponibili in località internazionali come Panama, Messico, Brasile e Svizzera, ma con il vantaggio di cure basate negli Stati Uniti. La clinica utilizza cellule staminali da cordone ombelicale e si concentra sul trattamento di condizioni come infiammazione, malattie autoimmuni e problematiche ortopediche.
I principali vantaggi includono cellule staminali di alta qualità provenienti da fonti etiche, comodità domestica che elimina la necessità di viaggi internazionali e operazioni sotto le regolamentazioni sanitarie della FDA statunitense, enfatizzando sicurezza e trasparenza.
Adia Nutrition (OTC Pink: ADIA) ha entrado en el mercado global de células madre de 15.1 mil millones de dólares a través de su división médica, Adia Med, con la apertura de su primera clínica en Winter Park, Florida. La instalación ofrece tratamientos con células madre utilizando productos celulares y basados en tejidos humanos (HCT/P) conformes a la normativa FDA 361.
La empresa tiene como objetivo proporcionar tratamientos comparables a los de ubicaciones internacionales como Panamá, México, Brasil y Suiza, pero con la ventaja de una atención basada en los EE. UU. La clínica utiliza células madre de cordón umbilical y se centra en tratar condiciones como inflamación, enfermedades autoinmunes y problemas ortopédicos.
Las principales ventajas incluyen células madre de alta calidad de fuentes éticas, comodidad local que elimina la necesidad de viajes internacionales y operaciones bajo las regulaciones de salud de la FDA de EE. UU., enfatizando la seguridad y la transparencia.
Adia Nutrition (OTC Pink: ADIA)는 151억 달러 규모의 글로벌 줄기세포 시장에 진입했습니다. 의료 부문인 Adia Med를 통해 플로리다주 윈터 파크에 첫 번째 클리닉을 개설했습니다. 이 시설은 FDA 규정을 준수하는 361 인간 세포, 조직 및 세포 및 조직 기반 제품(HCT/P)을 사용하는 줄기세포 치료를 제공합니다.
회사는 파나마, 멕시코, 브라질 및 스위스와 같은 해외 위치와 비교할 수 있는 치료를 제공하는 것을 목표로 하고 있지만, 미국 기반의 치료를 통해 이점을 제공합니다. 이 클리닉은 제대 줄기세포를 사용하고 염증, 자가면역 질환 및 정형외과 문제 치료에 중점을 둡니다.
주요 이점으로는 윤리적인 출처에서 제공되는 고품질 줄기세포, 해외 여행을 없애는 국내 편리함, 안전성과 투명성을 강조하는 미국 FDA 건강 규정에 따른 운영이 포함됩니다.
Adia Nutrition (OTC Pink: ADIA) a pénétré le marché mondial des cellules souches de 15,1 milliards de dollars grâce à sa division médicale, Adia Med, avec l'ouverture de sa première clinique à Winter Park, en Floride. L'établissement propose des traitements par cellules souches utilisant des produits cellulaires et tissulaires humains conformes aux exigences de la FDA 361.
L'entreprise vise à fournir des traitements comparables à ceux proposés dans des lieux internationaux comme le Panama, le Mexique, le Brésil et la Suisse, mais avec l'avantage d'un soin basé aux États-Unis. La clinique utilise des cellules souches de cordon ombilical et se concentre sur le traitement de conditions telles que l'inflammation, les maladies auto-immunes et les problèmes orthopédiques.
Les principaux avantages comprennent des cellules souches de qualité provenant de sources éthiques, la commodité d'un accès local éliminant le besoin de voyages internationaux, et une opération sous les réglementations sanitaires de la FDA, soulignant la sécurité et la transparence.
Adia Nutrition (OTC Pink: ADIA) hat den 15,1 Milliarden Dollar schweren globalen Markt für Stammzellen über seine medizinische Abteilung Adia Med betreten, indem es seine erste Klinik in Winter Park, Florida, eröffnet hat. Die Einrichtung bietet Stammzellbehandlungen mit FDA-konformen 361 menschlichen Zell-, Gewebes und zell- sowie gewebebasierten Produkten (HCT/P) an.
Das Unternehmen zielt darauf ab, Behandlungen anzubieten, die internationalen Standorten wie Panama, Mexiko, Brasilien und der Schweiz vergleichbar sind, jedoch mit dem Vorteil von in den USA basierter Versorgung. Die Klinik verwendet Stammzellen aus der Nabelschnur und konzentriert sich auf die Behandlung von Erkrankungen wie Entzündungen, Autoimmunerkrankungen und orthopädischen Problemen.
Wesentliche Vorteile umfassen qualitativ hochwertige Stammzellen aus ethischen Quellen, die Bequemlichkeit vor Ort, die internationale Reisen überflüssig macht, und Betriebe unter den Gesundheitsvorschriften der US-FDA, die Sicherheit und Transparenz betonen.
- Entry into $15.1 billion global stem cell market
- Successfully opened first U.S.-based treatment facility
- Offers FDA-compliant treatments domestically, reducing patient travel costs
- Competitive positioning against international treatment centers
- Operating in highly regulated market with strict FDA oversight
- Effectiveness of treatments varies widely and is still under research
- Faces competition from established international treatment centers
WINTER PARK, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Adia Nutrition Inc. (OTC Pink: ADIA), through its medical division Adia Med, is strategically positioning itself to capture a significant share of the growing
"With the global stem cell market expanding, we see an opportunity to make these treatments more accessible in the U.S.," said Larry Powalisz, CEO of Adia Nutrition. "Adia Med focuses on delivering care with advanced, ethically sourced umbilical cord stem cells."
Adia Med's treatment protocols are designed to align with practices from international clinics but emphasize:
- Quality Stem Cells: Utilizing umbilical cord stem cells noted for their potential in various medical applications.
- Convenience: Eliminating the need for patients to travel internationally for treatment, thus reducing associated uncertainties, logistics, and costs.
- Compliance and Safety: Operating under U.S. FDA health regulations, with a focus on safety, transparency, and ethical practices. Adia Med 361 HCT/Ps are vetted for FDA compliance ensuring safety and efficacy.
"Many patients have traveled abroad for treatments which we now offer locally in Florida," added Dr. Sher, Chief Stem Cell Medical Officer at Adia Med. "Our approach aims to offer treatments in a familiar, regulated setting with convenient follow-up care."
Adia Med's clinic has started treating patients for a range of conditions, including inflammation, autoimmune conditions and various orthopedic issues, exploring the potential of stem cell therapy in regenerative medicine. *
As Adia Nutrition enters this market, the company aims to enhance access to these treatments and contribute to the broader understanding and application of stem cell and other HCT/P therapies. Mr. Powalisz further stated, "Shareholders and investors, feel free to reach out to me to arrange a visit to our new clinic."
Disclaimer:
*Same Surgical Procedure Exception: HCT/Ps that are removed and implanted into the same individual during the same surgical procedure are exempt from FDA regulations under the "same surgical procedure exception" United States v. US Stem Cell Clinic, LLC, 403 F.Supp.3d 1279 (2019). This exception is limited to procedures where the HCT/P remains in its original form (United States v. California Stem Cell Treatment Center, Inc., 117 F.4th 1213 (2024).
Stem cell therapy is an area of ongoing research, and the effectiveness for various conditions can vary widely.
For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adia-med.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/eb28d356-23b2-409d-8843-bf223a7a9631
https://www.globenewswire.com/NewsRoom/AttachmentNg/aa5e7fd4-8b58-434e-b891-05ff64b124de
FAQ
What is the market size that Adia Nutrition (ADIA) is entering with its stem cell treatments?
Where is Adia Nutrition's (ADIA) first stem cell treatment facility located?
What types of conditions does Adia Med (ADIA) treat with stem cell therapy?
What type of stem cells does Adia Med (ADIA) use in its treatments?
How does Adia Med's (ADIA) treatment compare to international stem cell clinics?
